To augment insight from the ALTER-L001 trial and to increase evidence on the choice of anlotinib as an add-on therapy to ongoing systemic therapy in the context of primary treatment, we carried out this real-world study to investigate the efficacy and safety of anlotinib for the treatment of EGFR mutant NSCLC patients who developed gradual or oligo-progression while on first-line third-generation EGFR TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.